Investigational drug · Phase 3
Inpegsomatropin
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Turner Syndrome, Idiopathic Short Stature, Adult Growth Hormone Deficiency.
Phase 3Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "Inpegsomatropin"
First trial start
2025
Apr 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Inpegsomatropin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Turner Syndrome
- Idiopathic Short Stature
- Adult Growth Hormone Deficiency
- Small for Gestational Age
Approved drugs for the same conditions: Growth hormone deficiency · Rare and genetic disease · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "Inpegsomatropin" as an intervention, largest first.
Xiamen Amoytop Biotech Co., Ltd.Industry
NCT07894341 · 300 participants (planned) · Start Sep 26, 2026 · Primary completion Aug 31, 2041
Drug: Inpegsomatropin Injection · For: Idiopathic Short Stature
Sites: Beijing, China; Changsha, China; Chengdu, China · 27 sites in all
- The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short StaturePivotal-lookingRecruiting
Xiamen Amoytop Biotech Co., Ltd.Industry
NCT06927310 · 300 participants (planned) · Start Apr 28, 2025 · Primary completion Mar 2026
Drug: Inpegsomatropin Injection; Recombinant Human Growth Hormone Injection · For: Idiopathic Short Stature
Sites: Hefei, China; Beijing, China; Chongqing, China · 38 sites in all
- The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational AgePivotal-lookingRecruiting
Xiamen Amoytop Biotech Co., Ltd.Industry
NCT07309562 · 141 participants (planned) · Start Jan 20, 2026 · Primary completion Mar 2028
Drug: Inpegsomatropin Injection; Inpegsomatropin Injection and 1 more · For: Small for Gestational Age
Sites: Beijing, China; Changchun, China; Changsha, China · 49 sites in all
- The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short StaturePivotal-lookingRecruiting
Xiamen Amoytop Biotech Co., Ltd.Industry
NCT07614152 · 84 participants (planned) · Start Jul 5, 2026 · Primary completion Mar 30, 2028
Drug: Inpegsomatropin-Injection; Givopegsomatropin Solution Injection · For: Turner Syndrome
Sites: Anyang, China; Beijing, China; Changsha, China · 51 sites in all
Xiamen Amoytop Biotech Co., Ltd.Industry
NCT07551804 · 36 participants (planned) · Start Jun 10, 2026 · Primary completion Dec 31, 2027
Drug: Inpegsomatropin Injection; Placebo for Inpegsomatropin Injection and 4 more · For: Adult Growth Hormone Deficiency
Sites: Beijing, China; Henan, China; Shanghai, China · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.